Trial Profile
A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in mycosis fungoides (MF)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Mycosis fungoides
- Focus Biomarker; Therapeutic Use
- 10 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrial.gov record.
- 16 Apr 2012 New trial record